Accelerate Data & Deal-Making Through China’s Trial Ecosystem

The Asia Clinical Acceleration Summit brings together senior biotech leaders and investors to explore how China’s fast and flexible clinical trial ecosystem, alongside emerging opportunities across Asia, can unlock earlier data, de-risk development, and increase company valuation.

What You'll Learn:

How China-enabled trials generate faster clinical data, strengthen valuation and investment narratives, and create BD momentum
How China's unique disease prevalence, spanning oncology, metabolic, rare, and infectious diseases, enables faster recruitment for conditions more common than in the US/Europe
When to pursue IND vs. IIT pathways - and how each impacts timelines, cost, control and future global development plans

How China-enabled clinical data can support U.S. and global regulatory filings, including key acceptance considerations

Practical execution insights: site and CRO selection, operational setup, communication barriers, and cultural dynamics in China and across Asia